Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2016 Oct 25;6:35868. doi: 10.1038/srep35868

Soluble P-selectin rescues viper venom–induced mortality through anti-inflammatory properties and PSGL-1 pathway-mediated correction of hemostasis

Der-Shan Sun 1,2, Pei-Hsun Ho 2, Hsin-Hou Chang 1,2,a
PMCID: PMC5078805  PMID: 27779216

Abstract

Venomous snakebites are lethal and occur frequently worldwide each year, and receiving the antivenom antibody is currently the most effective treatment. However, the specific antivenom might be unavailable in remote areas. Snakebites by Viperidae usually lead to hemorrhage and mortality if untreated. In the present study, challenges of rattlesnake (Crotalus atrox) venom markedly increased the circulating soluble P-selectin (sP-sel) level, but not P-selectin (P-sel, Selp−/−) mutants, in wild-type mice. Because sP-sel enhances coagulation through the P-selectin ligand 1 (PSGL-1, Selplg) pathway to produce tissue factor–positive microparticles, we hypothesized that increasing the plasma sP-sel level can be a self-rescue response in hosts against snake venom–mediated suppression of the coagulation system. Confirming our hypothesis, our results indicated that compared with wild-type mice, Selp−/− and Selplg−/− mice were more sensitive to rattlesnake venom. Additionally, administration of recombinant sP-sel could effectively reduce the mortality rate of mice challenged with venoms from three other Viperidae snakes. The antivenom property of sP-sel is associated with improved coagulation activity in vivo. Our data suggest that the elevation of endogenous sP-sel level is a self-protective response against venom-suppressed coagulation. The administration of recombinant sP-sel may be developed as a new strategy to treat Viperidae snakebites.

Venomous snakebites are a major cause of life-threatening human injury from poisonous animals worldwide1. Currently available data suggest that the true effects of snake bites are underestimated2. For example, snake bites are a crucial occupational hazard affecting farmers, plantation workers, herders, and fishermen; open-style habitation and the practice of sleeping on floors also expose people to snake bites2. Viperidae, a flourishing snake family, contains more than 200 species of venomous snakes belonging to two subfamilies: pit vipers (Crotalinae) and old-world vipers (Viperinae)3. These snakes eat small animals and hunt by striking and envenoming to immobilize and kill prey4. Their venom comprises various coagulation-disrupting proteins1,5, which can cause functional alterations in coagulation factors and platelets5,6,7,8,9,10,11,12,13,14,15,16,17,18,19; thus, snakebites by vipers usually lead to inflammation and hemorrhage1,2,5,20,21,22,23. Antivenom injection is a major treatment for venomous snakebites, but little high-quality data is available to support its effectiveness, particularly in cases with venom-elicited coagulopathy1,5,24,25. Additionally, treatment with antivenom is not risk free, and adverse effects are common and occasionally severe1. Furthermore, because snakebites usually occur within a snake habitat, the specific antivenom may not be available in local hospitals2. Therefore, an alternative treatment is needed for venom-induced coagulant defect.

P-selectin (P-sel), a cell-surface adhesion molecule, is a member of the selectin family and is expressed and stored in the intracellular vesicle α-granules of platelets and the Weibel–Palade bodies of endothelial cells. P-sel is translocated to cell surfaces after stimulation26 and binds to oligosaccharide sialylated Lewis x and heparan sulfate containing glycoproteins, particularly the primary ligand, P-sel ligand 1 (PSGL-1)27,28. Increase in circulating soluble P-sel (sP-sel) level is associated with thrombotic consumptive disorders such as disseminated intravascular coagulation and thrombotic thrombocytopenic purpura, which involves generalized hypercoagulation29. However, the pathophysiological role of sP-sel in these diseases remains unclear. Recombinant sP-sel treatment in mice is associated with induction of the procoagulant state30 and can correct hemostasis in a mouse model of hemophilia A through interaction with PSGL-1 to generate procoagulant tissue factor (TF)-positive microparticles (MPs) (TF+-MPs)31. In this study, we demonstrated that challenges of rattlesnake venom increases circulating sP-sel level in mice. Although the mechanism by which sP-sel induces the procoagulant state remains elusive, the increases in sP-sel and coagulation levels in venom-challenged mice may help the host survive hemorrhage pathogenesis. Therefore, we hypothesized that the increase in circulating sP-sel could be a self-rescue response against venom-induced bleeding. The relevant mechanism and potential applications are discussed.

Results

Mortality and abnormal coagulant pathogenesis induced by snake venom of Crotalus atrox

The rattlesnake (Crotalus atrox) venom–induced mortality in wild-type C57BL/6J mice was examined. An injection dose higher than 3 mg/kg was found to cause 100% mortality, whereas doses lower than 1 mg/kg were not lethal (Fig. 1A experiment outline; 1B, mortality; 1C, Kaplan–Meier survival curves). In mice injected with sublethal doses of venom (1 mg/kg), we found prolonged plasma clotting times, reduced platelet counts, and increased plasma sP-sel level, all of which indicated that the coagulation system was suppressed (Fig. 1D–F).

Figure 1. Mortality and abnormal coagulant pathogenesis induced by snake venom of Crotalus atrox, the western diamondback rattlesnake.

Figure 1

Open in a new tab

(A) Experiment outline; (B) survival rates of C57BL/6J mice challenged with different dosages of the venom (n = 9); (C) mortality of mice challenged with 3 mg/mL venom plotted as Kaplan–Meier curves (n = 9); (D) plasma-clotting time analyses (APTT: activated partial thromboplastin time; PT: prothrombin time) (ND: no detectable clotting); (E) indicated platelet counts and (F) plasma soluble P-selectin (sP-sel) (n = 6) (D–F); 3 independent experiments with 2 or 3 replicates). Control Ig vs. rP-sel-Fc, **P = 3.7 × 10−5 (C); vehicle vs. venom,*P < 0.05 (D–F). The mouse drawing used in this figure was originally published in the Blood journal: Huang, H. S., Sun, D. S., Lien, T. S. and Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood, 2010; 116: 5002–500958. © the American Society of Hematology.

P-selectin and P-selectin ligand 1 mutants are more sensitive to venom challenges than the wild type mice

Injections of sP-sel are known to induce a procoagulant state through interaction with P-selectin ligand 1 (PSGL-1), which leads to the production of tissue factor–positive MPs (TF+-MPs) that are beneficial for a suppressed coagulation system in the hemophilia A mouse model31. Therefore, we hypothesized that the elevation of circulating sP-sel could be a native self-rescue response to counteract the suppressed coagulation system. Thus, compared with wild-type mice, P-sel knockout (KO) mice should be more sensitive to venom challenges because they do not produce sP-sel. Similarly, because sP-sel requires functional PSGL-1 to cause an increase in TF+-MP counts, PSGL-1 KO mice should be more sensitive to venom challenges compared with the parental strain. In the present study, we used sublethal doses of snake venom for wild-type mice to treat P-sel and PSGL-1 KO mice. In agreement with our hypothesis, we found that a sublethal dose of snake venom (1 mg/kg; Fig. 1B) markedly increased soluble P-sel in the wild-type and PSGL-1 (Selplg−/−) KO mice, but not in P-sel (Selp−/−) KO mice (Fig. 2A experiment outline, and 2B). In addition, a sublethal dose for wild-type mice (1 mg/kg; Fig. 1B) was lethal in P-sel KO mice and PSGL-1 KO mice (Fig. 2C,D). These results suggest that P-sel and PSGL-1 are vital for mice to counteract snake venom–mediated toxicity.

Figure 2. Soluble P-selectin (sP-sel) levels and mortality in venom-treated mice.

Figure 2

Open in a new tab

(A) Experiment outline, Crotalus atrox venom (1 mg/kg) elicited; (B) sP-sel levels (% of respective vehicle controls); (C) mortality in wild-type (C57BL/6J; Selp+/+, Selplg+/+) vs. P-sel KO (C57BL/6J; Selp−/−); (D) wild-type vs. PSGL-1 KO (C57BL/6J; Selplg−/−). *P < 0.05, venom vs. respective vehicle groups, n = 9 (B). ND: none detectable. Mortality is plotted as Kaplan–Meier curves [WT vs. KO, **P = 3.7 × 10−5 (C); *P = 2.7 × 10−2 (D), n = 9]. The mouse drawing used in this figure was originally published in the Blood journal: Huang, H. S., Sun, D. S., Lien, T. S. and Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood, 2010; 116: 5002–500958. © the American Society of Hematology.

Injection of recombinant sP-sel-IgG Fc fusion protein rescues venom-challenged mice

To further determine whether injections of sP-sel were beneficial to the mice during venom challenges, the rescue effect of the injection of recombinant sP-sel in venom-challenged mice was investigated. Our data indicated that recombinant P-sel IgG-Fc fusion protein (rP-sel-Fc) exerted a protective effect against venom-induced mortality in mice (Fig. 3A experiment outline, 3B,C). In addition, treatments of rP-sel-Fc markedly improved the coagulant parameters, including suppressed TF+-MPs levels and prolonged plasma clotting time and thrombocytopenia in venom-challenged mice (1 mg/kg, a sublethal dose; Fig. 3D–F).

Figure 3. Recombinant sP-sel-IgG Fc fusion protein (rP-sel-Fc)-mediated rescue in venom-challenged mice.

Figure 3

Open in a new tab

(A) Experiment outline; (B,C) rP-sel-Fc-rescued mortality (n = 9); (D) plasma-clotting time APTT and PT; (E) indicated tissue factor-positive microparticles (TF+-MPs) of the venom-treated mice. ND: no detectable clotting (n = 6) (D–F); 3 independent experiments with 2 or 3 replicates). **P = 3.7 × 10−5, control Ig vs. rP-sel-Fc (C), †P < 0.05, vehicle vs. venom, *P < 0.05, venom vs. venom + rP-sel-Fc groups (D–F). The mouse drawing used in this figure was originally published in the Blood journal: Huang, H. S., Sun, D. S., Lien, T. S. and Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood, 2010; 116: 5002–500958. © the American Society of Hematology.

Anti-P-sel neutralizing Ig-mediated rescue

Because PSGL-1 KO mice are less sensitive than the P-sel KO mice (Fig. 2C vs. 2D), and because PSGL-1 is essential for the induction of TF+-MPs in eliciting a procoagulant response31, our results suggest that additional protective mechanisms may be involved. Because P-sel is an adhesion molecule on platelets and endothelial cells that mediates the interaction of these cells with leukocytes, recombinant sP-sel and P-sel-neutralizing antibodies can block leukocyte infiltration to the inflamed tissues and exert an anti-inflammatory effect27. Thus, in addition to the coagulant-modulation effect, the anti-inflammatory effect of sP-sel may contribute to the protection against venom challenges. To investigate this possibility, we employed a P-sel-neutralizing antibody. We found that, although not fully protected, injections of the P-sel neutralizing antibody tended to reduce the circulating levels of proinflammatory cytokines TNF-α and IL-1β, and markedly reduced the mortality rate of venom-challenged mice (Fig. 4A experiment outline, 4B–D). These results suggest that the anti-inflammatory effect is also involved in sP-sel-mediated amelioration of snake venom–induced mortality in mice.

Figure 4. Anti-P-sel neutralizing Ig (anti-P-sel Ig)-mediated rescue.

Figure 4

Open in a new tab

(A) Experiment outline; (B,C) anti-P-sel Ig-mediated reduction of mouse circulating TNF-α and IL-1β (n = 6); (D) indicated mortality (n = 9) of venom-treated mice. †P < 0.05, vs. vehicle groups, *P < 0.05, vs. control Ig groups (B,C). **P = 3.7 × 10−5, ††P = 1 × 10−2, vs. control Ig groups (D). The mouse drawing used in this figure was originally published in the Blood journal: Huang, H. S., Sun, D. S., Lien, T. S. and Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood, 2010; 116: 5002–500958. © the American Society of Hematology.

The rP-sel-Fc mediated rescue of challenges with different viper venoms in mice

We hypothesized that elevation of circulating sP-sel is a native response to overcome venom-induced inflammation and coagulopathy. Therefore, rP-sel-Fc injection–mediated rescue could be applied to rescue pathogenesis induced by venom of other vipers. To test this hypothesis, mice were challenged with venoms from two rattlesnakes, Crotalus adamanteus and Crotalus basiliscus, and a viper, Agkistrodon contortrix. Mortality analysis indicated that treatments of sP-sel markedly rescued the lethal injections of aforementioned three snake venoms in mice (Fig. 5A experiment outline, 5B–D).

Figure 5. rP-sel-Fc-mediated rescue of viper venom-induced mortality in mice.

Figure 5

Open in a new tab

(A) Experiment outline and indicated lethal dose injections using venoms from (B) Crotalus adamanteus (eastern diamondback rattlesnake), (C) Crotalus basiliscus (mexican west-coast rattlesnake), and (D) Agkistrodon contortrix (copperhead) in the mouse model. Mortality is plotted as Kaplan–Meier curves (control Ig vs. rP-sel-Fc, **P = 3.7 × 10−5, n = 9) (B–D). The mouse drawing used in this figure was originally published in the Blood journal: Huang, H. S., Sun, D. S., Lien, T. S. and Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood, 2010; 116: 5002–500958. © the American Society of Hematology.

Our results showed that snake venom injections increased circulating sP-sel level and that this increase had a beneficial effect in mice during snake venom challenges.

Discussion

Blood circulation plays a vital role in the survival of vertebrates, including humans. Problems in blood circulation could be lethal. Hemostasis is the first line of defense against bleeding. Hemostasis involves both clot formation (coagulation) and clot dissolution (fibrinolysis), opposite cooperative processes that keep the hemodynamic properties of the blood constant32. The venoms of Viperidae snakes contain proteins that can be classified as coagulants, anticoagulants, and fibrinolytic factors19. Snakebites usually result in persistent bleeding because the venoms cause considerable degradation of fibrinogen and involve other coagulant factors, which affect platelet function, thus preventing clot formation19,33. However, whether an emergency assistance system exists in vivo to rescue such abnormal coagulation status remains unknown.

Increased levels of circulating sP-sel is observed in various thrombotic consumptive disorders such as heparin-induced thrombocytopenia and haemolytic uremic syndrome, which involve the induction of a procoagulant status29. Increased sP-sel level has also been observed in coagulation disorders, infectious diseases, and even tumors34. Consequently, an increased plasma sP-sel level has been considered a disease marker in abnormalities involving vascular damage, in vivo platelet activation, and thrombosis34,35,36. By contrast, the physiological roles of sP-sel in these diseases remain unclear and have rarely been reported.

Treatments with exogenous rP-sel-Fc have been demonstrated to correct the hemostasis of mice with hemophilia A through interaction with PSGL-1 to elicit procoagulant TF+-MPs31. If rP-sel-Fc treatments are beneficial for a hemorrhage-prone condition, the elevation of endogenous circulating sP-sel may be a protective response against bleeding. Moreover, increased sP-sel level has been observed in other hemorrhagic diseases such as dengue hemorrhagic fever37, immune thrombocytopenia38,39, and subarachnoid hemorrhage40. Despite the findings, the role of sP-sel in these disorders remains unclear. Hemorrhage is a major manifestation of venomous snakebites5,19. The hemorrhagic pathogeneses are mediated through the suppression of coagulation factors and platelets19,33. In this study, we report that snake venoms increased plasma sP-sel level in mice. We hypothesized that the increase in sP-sel level is a self-rescue response that led to amelioration of venom-mediated hemorrhage. We found that treatment with recombinant sP-sel markedly ameliorated venom-induced pathogenesis and reduced the mortality rate in mice.

The induction of procoagulation by rP-sel-Fc treatment is mediated through the interaction between rP-sel-Fc and PSGL-131, which suggests that both P-sel and PSGL-1 are essential in counteracting the toxic effects of snake venoms. P-sel and PSGL-1 KO mice are more sensitive to venom challenges compared with wild-type mice. In addition, injections of sP-sel markedly rescued clotting defect and reduced mortality rates in mice. Circulating sP-sel or P-sel neutralizing antibodies also exerted an anti-inflammatory effect by blocking the interaction between endothelial P-sel and leukocyte PSGL-1 to prevent leukocyte infiltration and inflammation in the inflamed tissues27. Therefore, we used a sP-sel neutralizing antibody for comparison. We found that the anti-P-sel Ig also exerted a rescuing effect in venom-challenged mice, even though rP-sel-Fc ameliorated venom-stimulated inflammation and mortality more efficiently compared with the anti-P-sel Ig (Fig. 4). These results collectively suggested that both procoagulant (Fig. 3, upregulating TF+-MPs) and anti-inflammatory (Fig. 4) properties of sP-sel are involved in the rescue of venom-induced pathogenesis.

Here, we propose a model of sP-sel-mediated amelioration of snake venom–induced toxicity (Fig. 6), in which two rescue pathways are involved. In pathway 1, venom-induced stress upregulates circulating sP-sel level (Fig. 6A,B), which exerts anti-inflammatory effects and thus reduces inflammation (Fig. 6C,D). In pathway 2, through a PSGL-1-dependent pathway, sP-sel increases the circulating TF+-MP counts to induce a procoagulant state for counteracting venom-mediated suppression of the coagulation system (Fig. 6E–G).

Figure 6. Hypothetical model for sP-sel-mediated rescue of venomous viper snakebites.

Figure 6

Open in a new tab

Data suggest that two rescue pathways are involved. Rescue pathway 1 involves a sP-sel-mediated anti-inflammatory regulation (A–D). Rescue pathway 2 involves sP-sel and P-sel ligand-1 (PSGL-1)-mediated elicitation of circulating tissue factor-positive microparticles (TF+-MPs) for rebalancing the coagulation system (A–B to E–G). The mouse drawing used in this figure was originally published in the Blood journal: Huang, H. S., Sun, D. S., Lien, T. S. and Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood, 2010; 116: 5002–500958. © the American Society of Hematology.

According to this model, however, if the venom induced a hypercoagulable state, how can the procoagulant property of sP-sel still rescue the envenoming host? There are three possible explanations. First, venom-induced hypercoagulation (<2 h; Fig. 1A,D, APTT, PT already prolonged and shifted to hypocoagulation within 2 h; Suppl. Fig. 1C-2, blue labels) and sP-sel-elicited procoagulation (>6 h; Suppl. Fig. 2) do not appear simultaneously. The anti-inflammatory and procoagulant properties of sP-sel are elicited according to chronological order. We found that rP-sel-Fc exerted its anti-inflammatory property relatively quickly, within one hour (Suppl. Fig. 3, control Ig vs. rP-sel-Fc groups), as compared with the slow induction of procoagulation activity, which required up to six hours (Suppl. Fig. 2, control Ig vs. rP-sel-Fc groups). This is likely due to anti-inflammation, which can be more easily and immediately induced by the competing interaction of P-sel with its ligands (Fig. 6C); whereas the procoagulant effect requires more time to further elicit TF+-MPs (Fig. 6E–G). A period of 6–72 h was required for sP-sel to induce a considerable level of procoagulant TF+-MPs in vivo41. Second, inflammatory mediators can induce thrombosis and procoagulant responses42,43,44,45; and anti-inflammatory treatments can also ameliorate hypercoagulation and vaso-occlusion in vivo46,47. This suggests that the first initiated anti-inflammatory effect of sP-sel (Fig. 6B–D, pathway 1) should also, at least in part, participate in the reduction of hypercoagulation burden and preserve functional coagulation machineries, such as platelets and plasma coagulation factors, following the venom challenges. This is in agreement with our data (Fig. 3D,F, venom vs. venom + rP-sel-Fc groups). Third, our TNF-α analysis revealed that snake venom induced the greatest pathological impact within the first hour (Suppl. Fig. 3, 1 h groups); the envenoming mice gradually recovered from the acute inflammatory phase following the second hour after the venom challenges (reduced TNF-α levels; Suppl. Figs 3, 2 and 4 h groups). Therefore, according to the protective effect demonstrated in this study, the late induction of the procoagulant effect of sP-sel involves an intricate regulation that is likely elicited in the last possible moment during the recovery phase for the prevention of hemorrhage and related complications.

Accordingly, our model can also be illustrated in a chronological order, in which pathways 1 and 2 in Fig. 6 are indicated as innate immune and coagulation balance, respectively (Fig. 6; Suppl. Fig. 1A, normal; Suppl. Fig. 1B–D, sP-sel-mediated rebalance from envenomation pathogenesis). Note that here, we highlighted a process in Suppl. Fig. 1B–C, in which the snake venom-induced hypercoagulation is converted to hypocoagulation due to overconsumption of platelets and coagulation factors1,5,25,48. This process causes secondary complications, namely hypocoagulation and hemorrhage1,5,49. The procoagulant property of sP-sel is theoretically helpful for rescuing the coagulant defect at this stage. Notably, sP-sel-induced TF+-MPs preferentially translocate to the sites of injuries and facilitate thrombi formation50,51. This is beneficial for rebalancing coagulation hemostasis to stop bleeding specifically at the damaged tissues. Several P-sel blocking agents are currently under clinical trials for managing inflammatory and vascular diseases27,52,53. These agents may be useful to control snake venom-induced complications, as we have demonstrated in the ameliorative effect of anti-P-sel Ig in this study. However, when compared with rP-sel-Fc, these agents do not possess the property for triggering the PSGL-1-mediated procoagulant rescue pathway (Fig. 6, pathway 2); therefore, their rescue efficiency for envenomation is theoretically lower than that of rP-sel-Fc. However, because rP-sel-Fc has procoagulant properties, additional developments involving rP-sel-Fc and any form of sP-sel should be considered with caution when determining the optimal dosage for preventing overdose-induced hypercoagulation. Additionally, whether history of cardiovascular disease influences the treatment outcome of rP-sel-Fc is also a critical categories warranting further investigation.

In summary, our data suggest that the sP-sel-mediated enhancement of hemostasis has therapeutic potential in clinical settings involving deficient coagulation. In contrast to coagulation-suppressive drugs, coagulation-enhancing agents have rarely been developed, likely because of the risk of thrombosis. Consequently, an effective coagulation-enhancing agent suitable for managing internal hemorrhage in the acute phase is still urgently needed. Circulating sP-sel has been considered a marker of various disorders and plays a pathological role in various diseases. Here, we demonstrated that injections of rP-sel-Fc are beneficial for mice in surviving snake venom-challenges, suggesting that an increase in sP-sel is a physiological response of hemostasis. Therefore, as a major component of a hemorrhage-elicited self-rescue response, sP-sel may be useful in the development of a new therapy for managing hemorrhage-related diseases such as venomous snakebites. This may be particularly useful for health care agencies in remote areas that cannot afford to maintain diverse antivenoms.

Materials and Methods

Chemicals, antibodies and snake venom

Chemicals and all snake venoms were purchased from Sigma-Aldrich (St. Louis, MO). An anti-P-sel antibody and an isotype control Ig were purchased from BD Pharmingen Taiwan (Taipei, Taiwan) and Enzo Life Sciences (Blossom Biotechnologies, Taipei, Taiwan), respectively. Recombinant P-sel IgG-Fc fusion protein (rP-sel-Fc) was purchased from R&D Systems (Minneapolis, MN). Using previously described immunization methods54,55,56,57, polyclonal anti-P-sel Igs were obtained from rP-sel-Fc immunized rabbits for neutralization analysis.

Mice

The C57BL/6J wild-type mice (males, 8–12 weeks old) were purchased from the National Laboratory Animal Center (NLAC), Taipei, Taiwan. C57BL/6J mice deficient in P-selectin (Selp−/−; B6.129S-Selptm1Bay/J)58 and P-selectin ligand 1 (PSGL-1) (Selplg−/−; B6.129-Selplgtm1Rpmc/J) were obtained from the Jackson Laboratory (Bar Harbor, ME). These KO mice were backcrossed with the parental C57BL/6J mouse strain for at least six generations. All mouse strains were housed in the Laboratory Animal Center of Tzu Chi University. At the end of the experiment, the surviving mice were then euthanized with CO2 following the National Institutes of Health guideline59. In the mortality experiments, the mice were examined every 12 h for up to 7 d. No additional death was observed 7 d after the LT treatments because all surviving mice were monitored every day for 2 mo. Experimental methods in this study were conducted in agreement with National (Taiwan Animal Protection Act, 2008) directive for protection of laboratory animals. All experimental protocols for examining the experimental animals were approved by the Animal Care and Use Committee of Tzu-Chi University, Hualien, Taiwan (approval ID: 103050, 103058).

Experimental administration

In the mice experiments, reagents were intravenously injected through the retro-orbital venous plexus60,61 using the following doses: rP-sel-Fc, 1.2 mg/kg30; anti-P-sel Ig, 1.2 mg/kg; and isotype control IgG, 1.2 mg/kg. The isotype-matched control IgG was used as a control protein in the in vivo experiments because rP-sel is an IgG-Fc fusion protein. Venom doses were using as following: Crotalus atrox: sublethal doses 0.2 mg/kg, 1 mg/kg; lethal doses 3 mg/kg, 6 mg/kg. Crotalus adamanteus: lethal dose 3 mg/kg. Crotalus basiliscus: lethal dose 12 mg/kg. Agkistrodon contortrix: lethal dose 4 mg/kg.

Plasma clotting time analysis

The plasma recalcification clotting time was measured using previously described methods30,59. Before (0 h) and after (2, 4 and 6 h) the treatments of control Ig and rP-sel-Fc, the blood samples of mice were collected from their retro-orbital venous plexus using plain capillary tubes (Thermo Fisher Scientific Taiwan, Taipei, Taiwan) and collected into polypropylene tubes (Eppendorf; Fisher Scientific) containing anticoagulant acid-citrate-dextrose solution (ACD; 38 mM citric acid, 75 mM sodium citrate, 100 mM dextrose)8,58,59,62. Platelet-poor plasma (PPP) was prepared by centrifugation at 1,500 × g for 20 min. PPP was centrifuged once again for 3 min at 15,000 × g to remove contaminating cells from the plasma. Plasma clotting was induced under stirring conditions (800 rpm) at 37 °C in an aggregometer (Model 600B, Ion-Trace, Stouffville, Canada)63 by adding a volume of prewarmed 20 mM CaCl2 solution to an equal volume of plasma in a siliconized tube. The time (in seconds) needed to clot was determined. The activated partial thromboplastin time (APTT) and prothrombin time (PT) of mice challenged with snake venoms were measured. APTT and PT analyses were performed using a coagulometer (ACL-Futura Plus, Instrumentation Laboratory, Milan, Italy), following the manufacturer’s instructions as described59,64,65.

Platelet count analysis

Whole blood (50–80 μl) samples of mice were collected from retro-orbital venous plexus and mixed with anticoagulant ACD solution in Eppendorf tubes. Platelet counts were then measured by a hematology analyzer (KX-21N, Sysmex) as described58,60.

ELISA and flow cytometry analysis

A standard ELISA protocol was conducted55,66 using a microplate reader as previously described67,68,69. The circulating levels of sP-sel, IL-1β and TNF-α of experimental mice were determined by mouse sP-Selectin/CD62P, IL-1β and TNF-α ELISA kits (R&D Systems and BioLegend, San Diego, CA)56,69; calculations were made by comparing the specific sP-sel, IL-1β and TNF-α values with standard curves of titrated P-sel, IL-1β and TNF-α, respectively. Mouse microparticle (MPs) rich plasma was prepared by removing blood cells (including platelets) through centrifugation. To analyze the surface tissue factor (TF) expression of mouse MPs, a flow cytometer (FACScalibur, BD Biosciences, CA) was used58,62. Fluorescent anti-TF antibody was purchased from Abcam (Cambridge, MA).

Statistics

The means, standard deviations, and statistics of the experimental data were quantified using software Microsoft Office Excel 2003, SigmaPlot 10, and SPSS 17. The statistical significance of the data was further determined using one-way ANOVA followed by a post hoc Bonferroni-corrected t test. The Kaplan Meier curves are plotted using the Online Application for the Survival Analysis of Lifespan Assay (http://sbi.postech.ac.kr/oasis)70. A probability of type 1 error α = 0.05 was determined to be the threshold of statistical significance.

Additional Information

How to cite this article: Sun, D.-S. et al. Soluble P-selectin rescues viper venom–induced mortality through anti-inflammatory properties and PSGL-1 pathway-mediated correction of hemostasis. Sci. Rep. 6, 35868; doi: 10.1038/srep35868 (2016).

Supplementary Material

Supplementary Information
srep35868-s1.doc (481.5KB, doc)
Supplementary Information
srep35868-s2.doc (481.5KB, doc)

Acknowledgments

The authors wish to thank the colleagues in the Laboratory Animal Centers of Tzu-Chi University, Hualien, for their support in the animal experiments. We are also grateful to the grant supports from Ministry of Science and Technology, R.O.C. (104-2320-B-320 -009 -MY3), and Tzu-Chi University, Buddhist Tzu-Chi Foundation, and Buddhist Tzu Chi Medical Foundation (TCIRP 95002, TCIRP 98001, TCIRP 101001-01, TCRPP103001-01 and TCMMP104-06).

Footnotes

Author Contributions D.-S.S. and H.-H.C. conceived and designed the experiments. P.-H.H. and H.-H.C. performed the experiments. P.-H.H. analyzed the data. H.-H.C. wrote the main manuscript text.

References

  1. Maduwage K. & Isbister G. K. Current treatment for venom-induced consumption coagulopathy resulting from snakebite. PLoS Negl Trop Dis 8, e3220, 10.1371/journal.pntd.0003220 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alirol E., Sharma S. K., Bawaskar H. S., Kuch U. & Chappuis F. Snake bite in South Asia: a review. PLoS Negl Trop Dis 4, e603, 10.1371/journal.pntd.0000603 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Castoe T. A. & Parkinson C. L. Bayesian mixed models and the phylogeny of pitvipers (Viperidae: Serpentes). Mol Phylogenet Evol 39, 91–110, 10.1016/j.ympev.2005.12.014 (2006). [DOI] [PubMed] [Google Scholar]
  4. Martins M., Marques O. & Sazima I. In Biology of the vipers (eds Schuett G., Hoggren M. & Douglas M. E.) (Eagle Mountain Publishing, 2002). [Google Scholar]
  5. Berling I. & Isbister G. K. Hematologic effects and complications of snake envenoming. Transfus Med Rev 29, 82–89, 10.1016/j.tmrv.2014.09.005 (2015). [DOI] [PubMed] [Google Scholar]
  6. Chang H. H. et al. Rhodostomin, an RGD-containing peptide expressed from a synthetic gene in Escherichia coli, facilitates the attachment of human hepatoma cells. Biochem Biophys Res Commun 190, 242–249 (1993). [DOI] [PubMed] [Google Scholar]
  7. Chang H. H., Kau J. H., Lo S. J. & Sun D. S. Cell-adhesion and morphological changes are not sufficient to support anchorage-dependent cell growth via non-integrin-mediated attachment. Cell Biol Int 27, 123–133 (2003). [DOI] [PubMed] [Google Scholar]
  8. Chang H. H., Lin C. H. & Lo S. J. Recombinant rhodostomin substrates induce transformation and active calcium oscillation in human platelets. Exp Cell Res 250, 387–400 (1999). [DOI] [PubMed] [Google Scholar]
  9. Chang H. H. & Lo S. J. Full-spreading platelets induced by the recombinant rhodostomin are via binding to integrins and correlated with FAK phosphorylation. Toxicon 36, 1087–1099 (1998). [DOI] [PubMed] [Google Scholar]
  10. Chang H. H., Tsai W. J. & Lo S. J. Glutathione S-transferase-rhodostomin fusion protein inhibits platelet aggregation and induces platelet shape change. Toxicon 35, 195–204 (1997). [DOI] [PubMed] [Google Scholar]
  11. Sun D. S. et al. Calcium oscillation and phosphatidylinositol 3-kinase positively regulate integrin alpha(IIb)beta3-mediated outside-in signaling. J Biomed Sci 12, 321–333, 10.1007/s11373-005-0979-6 (2005). [DOI] [PubMed] [Google Scholar]
  12. Chang H. H. & Lo S. J. Rhodostomin, a snake venom disintegrin, served as a molecular tool to dissect the integrin function. Toxin Reviews 26, 189–202 (2008). [Google Scholar]
  13. Chang C. P., Chang J. C., Chang H. H., Tsai W. J. & Lo S. J. Positional importance of Pro53 adjacent to the Arg49-Gly50-Asp51 sequence of rhodostomin in binding to integrin alphaIIbbeta3. Biochem J 357, 57–64 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sun D. S. et al. PI3-kinase is essential for ADP-stimulated integrin alpha(IIb)beta3-mediated platelet calcium oscillation, implications for P2Y receptor pathways in integrin alpha(IIb)beta3-initiated signaling cross-talks. J Biomed Sci 12, 937–948, 10.1007/s11373-005-9016-z (2005). [DOI] [PubMed] [Google Scholar]
  15. Chang H. H., Chang C. P., Chang J. C., Dung S. Z. & Lo S. J. Application of Recombinant Rhodostomin in Studying Cell Adhesion. J Biomed Sci 4, 235–243 (1997). [DOI] [PubMed] [Google Scholar]
  16. Lo S. J. & Chang H. H. Recombinant snake disintegrins used for mammalian integrin study. Toxin Reviews 24, 95–111 (2005). [Google Scholar]
  17. Chang J. C., Chang H. H., Lin C. T. & Lo S. J. The integrin alpha6beta1 modulation of PI3K and Cdc42 activities induces dynamic filopodium formation in human platelets. J Biomed Sci 12, 881–898, 10.1007/s11373-005-9021-2 (2005). [DOI] [PubMed] [Google Scholar]
  18. Chang H. H., Shih K. N. & Lo S. J. Receptor-mediated endocytosis as a selection force to enrich bacteria expressing rhodostomin on their surface. J Biomed Sci 7, 42–50, 25428 (2000). [DOI] [PubMed] [Google Scholar]
  19. Braud S., Bon C. & Wisner A. Snake venom proteins acting on hemostasis. Biochimie 82, 851–859 (2000). [DOI] [PubMed] [Google Scholar]
  20. Hifumi T. et al. Venomous snake bites: clinical diagnosis and treatment. J Intensive Care 3, 16, 10.1186/s40560-015-0081-8 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sunitha K. et al. Inflammation and oxidative stress in viper bite: an insight within and beyond. Toxicon 98, 89–97, 10.1016/j.toxicon.2015.02.014 (2015). [DOI] [PubMed] [Google Scholar]
  22. Teixeira Cde F., Fernandes C. M., Zuliani J. P. & Zamuner S. F. Inflammatory effects of snake venom metalloproteinases. Mem Inst Oswaldo Cruz 100 Suppl 1, 181–184, /S0074-02762005000900031 (2005). [DOI] [PubMed] [Google Scholar]
  23. Nanjaraj Urs A. N. et al. Progressive Hemorrhage and Myotoxicity Induced by Echis carinatus Venom in Murine Model: Neutralization by Inhibitor Cocktail of N,N,N′,N′-Tetrakis (2-Pyridylmethyl) Ethane-1,2-Diamine and Silymarin. PLoS One 10, e0135843, 10.1371/journal.pone.0135843 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Isbister G. K. et al. Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10). J Thromb Haemost 8, 2504–2513, 10.1111/j.1538-7836.2010.04050.x (2010). [DOI] [PubMed] [Google Scholar]
  25. Isbister G. K. Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy. Semin Thromb Hemost 35, 93–103, 10.1055/s-0029-1214152 (2009). [DOI] [PubMed] [Google Scholar]
  26. McEver R. P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thrombosis and haemostasis 86, 746–756 (2001). [PubMed] [Google Scholar]
  27. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 9, 263–268 (2003). [DOI] [PubMed] [Google Scholar]
  28. Cambien B. & Wagner D. D. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 10, 179–186, 10.1016/j.molmed.2004.02.007 (2004). [DOI] [PubMed] [Google Scholar]
  29. Chong B. H. et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83, 1535–1541 (1994). [PubMed] [Google Scholar]
  30. Andre P., Hartwell D., Hrachovinova I., Saffaripour S. & Wagner D. D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 97, 13835–13840, 10.1073/pnas.250475997 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hrachovinova I. et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 9, 1020–1025 (2003). [DOI] [PubMed] [Google Scholar]
  32. Davie E. W., Fujikawa K. & Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363–10370 (1991). [DOI] [PubMed] [Google Scholar]
  33. Kini R. M. Toxins in thrombosis and haemostasis: potential beyond imagination. J Thromb Haemost 9 Suppl 1, 195–208, 10.1111/j.1538-7836.2011.04279.x (2011). [DOI] [PubMed] [Google Scholar]
  34. Barron E., Lara J., White M. & Mathers J. C. Blood-borne biomarkers of mortality risk: systematic review of cohort studies. PloS one 10, e0127550, 10.1371/journal.pone.0127550 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Blann A. D., Lip G. Y., Beevers D. G. & McCollum C. N. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thrombosis and haemostasis 77, 1077–1080 (1997). [PubMed] [Google Scholar]
  36. Zonneveld R. et al. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care 18, 204, 10.1186/cc13733 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Michels M. et al. Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. Am J Trop Med Hyg 87, 943–946, 10.4269/ajtmh.2012.12-0020 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Olcay L., Yenicesu I. & Yetgin S. Soluble P-selectin, interleukin 6, and thrombopoietin levels in children with acute and chronic idiopathic thrombocytopenic purpura and their relationship with mega-dose methylprednisolone therapy: a pilot study. J Pediatr Hematol Oncol 24, 742–745 (2002). [DOI] [PubMed] [Google Scholar]
  39. Haznedaroglu I. C., Buyukasik Y., Kosar A., Kirazh S. & Dundar S. V. Thrombopoietin, interleukin-6, and P-selectin at diagnosis and during post-steroid recovery period of patients with autoimmune thrombocytopenic purpura. Ann Hematol 77, 165–170 (1998). [DOI] [PubMed] [Google Scholar]
  40. Frijns C. J., Kasius K. M., Algra A., Fijnheer R. & Rinkel G. J. Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 77, 863–867, 10.1136/jnnp.2005.081539 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Hrachovinova I. et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 9, 1020–1025, 10.1038/nm899 (2003). [DOI] [PubMed] [Google Scholar]
  42. Pircher J. et al. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther 14, R225, 10.1186/ar4064 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Fan J. et al. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am J Respir Cell Mol Biol 22, 412–421, 10.1165/ajrcmb.22.4.3857 (2000). [DOI] [PubMed] [Google Scholar]
  44. Shebuski R. J. & Kilgore K. S. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300, 729–735 (2002). [DOI] [PubMed] [Google Scholar]
  45. Foley J. H. & Conway E. M. Cross Talk Pathways Between Coagulation and Inflammation. Circ Res 118, 1392–1408, 10.1161/CIRCRESAHA.116.306853 (2016). [DOI] [PubMed] [Google Scholar]
  46. Emmi G. et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J 13, 15, 10.1186/s12959-015-0047-z (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Solovey A. A., Solovey A. N., Harkness J. & Hebbel R. P. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97, 1937–1941 (2001). [DOI] [PubMed] [Google Scholar]
  48. White J. Snake venoms and coagulopathy. Toxicon 45, 951–967, 10.1016/j.toxicon.2005.02.030 (2005). [DOI] [PubMed] [Google Scholar]
  49. Sotelo N. Review of treatment and complications in 79 children with rattlesnake bite. Clin Pediatr (Phila) 47, 483–489, 10.1177/0009922807311734 (2008). [DOI] [PubMed] [Google Scholar]
  50. Falati S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197, 1585–1598, 10.1084/jem.20021868 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Polgar J., Matuskova J. & Wagner D. D. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 3, 1590–1596, 10.1111/j.1538-7836.2005.01373.x (2005). [DOI] [PubMed] [Google Scholar]
  52. Kutlar A. et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 87, 536–539, 10.1002/ajh.23147 (2012). [DOI] [PubMed] [Google Scholar]
  53. Tardif J. C. et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol 61, 2048–2055, 10.1016/j.jacc.2013.03.003 (2013). [DOI] [PubMed] [Google Scholar]
  54. Sun D. S. et al. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. Journal of thrombosis and haemostasis: JTH 5, 2291–2299, 10.1111/j.1538-7836.2007.02754.x (2007). [DOI] [PubMed] [Google Scholar]
  55. Chang H. H. et al. Facilitation of cell adhesion by immobilized dengue viral nonstructural protein 1 (NS1): arginine-glycine-aspartic acid structural mimicry within the dengue viral NS1 antigen. J Infect Dis 186, 743–751 (2002). [DOI] [PubMed] [Google Scholar]
  56. Lien T. S. et al. Dengue virus and antiplatelet autoantibodies synergistically induce haemorrhage through Nlrp3-inflammasome and FcgammaRIII. Thromb Haemost 113, 1060–1070, 10.1160/TH14-07-0637 (2015). [DOI] [PubMed] [Google Scholar]
  57. Sun D. S. et al. Endothelial Cell Sensitization by Death Receptor Fractions of an Anti-Dengue Nonstructural Protein 1 Antibody Induced Plasma Leakage, Coagulopathy, and Mortality in Mice. J Immunol 195, 2743–2753, 10.4049/jimmunol.1500136 (2015). [DOI] [PubMed] [Google Scholar]
  58. Huang H. S., Sun D. S., Lien T. S. & Chang H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood 116, 5002–5009, 10.1182/blood-2010-03-275123 (2010). [DOI] [PubMed] [Google Scholar]
  59. Sun D. S. et al. Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice. Virulence 6, 466–475, 10.1080/21505594.2015.1031454 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Chen P. K. et al. Suppressive effects of anthrax lethal toxin on megakaryopoiesis. PLoS One 8, e59512, 10.1371/journal.pone.0059512 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Chang H. H. et al. Erythropoiesis suppression is associated with anthrax lethal toxin-mediated pathogenic progression. PLoS One 8, e71718, 10.1371/journal.pone.0071718 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Chang H. H. et al. Erythrocytic mobilization enhanced by the granulocyte colony-stimulating factor is associated with reduced anthrax-lethal-toxin-induced mortality in mice. PloS one 9, e111149, 10.1371/journal.pone.0111149 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Chang H. H. & Sun D. S. Methods of reducing hypoxic stress in a mammal by administering soluble P-selectin. US 8377887 B1 patent (2013).
  64. Kau J. H. et al. Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats. J Biomed Sci 19, 98, 10.1186/1423-0127-19-98 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Kau J. H. et al. Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets. J Infect Dis 192, 1465–1474, 10.1086/491477 (2005). [DOI] [PubMed] [Google Scholar]
  66. Shyu R. H. et al. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci 7, 51–57, 25429 (2000). [DOI] [PubMed] [Google Scholar]
  67. Wong M. S. et al. Antibacterial property of Ag nanoparticle-impregnated N-doped titania films under visible light. Sci Rep 5, 11978, 10.1038/srep11978 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Chen Y. L. et al. The use of nanoscale visible light-responsive photocatalyst TiO2-Pt for the elimination of soil-borne pathogens. PLoS One 7, e31212, 10.1371/journal.pone.0031212 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Wu M. S. et al. Nanodiamonds protect skin from ultraviolet B-induced damage in mice. J Nanobiotechnology 13, 35, 10.1186/s12951-015-0094-4 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Yang J. S. et al. OASIS: online application for the survival analysis of lifespan assays performed in aging research. PLoS One 6, e23525, 10.1371/journal.pone.0023525 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep35868-s1.doc (481.5KB, doc)
Supplementary Information
srep35868-s2.doc (481.5KB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES